Search for 'Provider:Blood,'

Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma.

By Valeri, Antonio | Martínez López, Joaquín. Blood, 2016 . 128(18):2241-52. , Formato Vancouver: Gutiérrez González A, Martínez Moreno M, Samaniego R, Arellano Sánchez N, Salinas Muñoz L, Relloso M et al. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood. 2016 Nov 3;128(18):2241-52.

Place Hold on Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma.

Treatment for patients with newly diagnosed multiple myeloma in 2015.

By Martínez López, Joaquín | Lahuerta Palacios, Juan José . Blood reviews, 2015 . 29(6):387-403. , Formato Vancouver: Mateos MV, Ocio EM, Paiva B, Rosiñol L, Martínez López J, Bladé J et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev. 2015 Nov;29(6):387-403.

Place Hold on Treatment for patients with newly diagnosed multiple myeloma in 2015.

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

By Martínez López, Joaquín | López Anglada, Lucía | Cedena Romero, María Teresa | Sáez Gómez, María Auxiliadora | Rapado Martínez, Inmaculada | Cueto Felgueroso, Cecilia | Lahuerta Palacios, Juan José . Blood, 2015 . 126(7):858-62. , Formato Vancouver: Martínez López J, Paiva B, López Anglada L, Mateos MV, Cedena T, Vidríales MB et al; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015 Aug 13;126(7):858-62.

Place Hold on Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

By Martínez López, Joaquín | Lahuerta Palacios, Juan José | Barrio García, Santiago | Ayala Díaz, Rosa María | Montalbán Pallarés, María Ángeles | Sopeña Corvinos, María | Cedena Romero, María Teresa | Rapado Martínez, Inmaculada. Blood, 2014 . 123(20):3073-9. , Formato Vancouver: Martínez López J, Lahuerta JJ, Pepín F, González M, Barrio S, Ayala R. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014 May 15;123(20):3073-9.

Place Hold on Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Hemolytic disease of the newborn due to anti-jkb: case report and review of the literature.

By Jiménez Ubieto, Ana Isabel | Velasco Rodríguez, Diego | Pérez Segura, Gloria | Montejano Ortega, Laura. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2014 . 30(2):135-8. , Formato Vancouver: Velasco Rodríguez D, Pérez-Segura G, Jiménez-Ubieto A, Rodríguez MA, Montejano L. Hemolytic disease of the newborn due to anti-jkb: case report and review of the literature. Indian J Hematol Blood Transfus. 2014 Jun;30(2):135-8.

Place Hold on Hemolytic disease of the newborn due to anti-jkb: case report and review of the literature.

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?.

By Martínez López, Joaquín | Montalbán Pallarés, María Ángeles | Lahuerta Palacios, Juan José . Blood, 2014 . 124(12):1887-93. , Formato Vancouver: Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood. 2014 Sep 18;124(12):1887-93.

Place Hold on GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?.

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.

By Cortijo Cascajares, Susana | Ruiz Ares, Gustavo | Cortés-Funes Castro, Hernán | Pernaut Sánchez, Cristina | Otero Blas, Irene | Rodríguez Garzotto, Analía. Journal of blood medicine, 2014 . 5:43-8 , Formato Vancocuver: Rodriguez Garzotto A, Cortijo Casacajares S, Pernaut C, Ruiz Ares GJ, Otero Blas I, Heine O et al. Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience. J Blood Med. 2014 Apr 28;5:43-8.

Place Hold on Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.

Diagnosis and treatment of resistant hypertension.

By Ruilope Urioste, Luis Miguel. Blood pressure, 2014 . 23(4):193-9. , Formato Vancouver: Waeber B, Volpe M, Ruilope LM, Schmieder RE. Diagnosis and treatment of resistant hypertension. Blood Press. 2014 Aug;23(4):193-9.

Place Hold on Diagnosis and treatment of resistant hypertension.

Compliance with Mineral Metabolism Targets in Haemodialysis Patients: Moving Backwards?.

By Praga Terente, Manuel. Blood purification, 2013 . 36(2):122-31. , Formato Vancouver: Palomares I, Ramos R, Martín-Malo A, Merello JI, Praga M, Luño J. ORD Group. Compliance with mineral metabolism targets in haemodialysis patients: moving backwards? Blood Purif. 2013;36(2):122-31.

Place Hold on Compliance with Mineral Metabolism Targets in Haemodialysis Patients: Moving Backwards?.

Blood Pressure Targets for Patients with Chronic Kidney Disease.

By Ruilope Urioste, Luis Miguel. Blood Pressure, 2013 . 22(6):395-6. , Formato Vancouver: Sarafidis PA, Ruilope LM. Blood pressure targets for patients with chronic kidney disease. Blood Pressure. 2013;22(6):395-6

Place Hold on Blood Pressure Targets for Patients with Chronic Kidney Disease.

Renin-Angiotensin-Aldosterone System Blockade in Hypertensive Patients with Chronic Kidney Disease

By Ruilope Urioste, Luis Miguel. Blood Pressure, 2013 . 22(6):397-8. , Formato Vancouver: Sarafidis PA, Ruilope LM. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management: Renin-Angiotensin-Aldosterone System Blockade in Hypertensive Patients with Chronic Kidney Disease. Blood Press.2013;22(6):397-8.

Place Hold on Renin-Angiotensin-Aldosterone System Blockade in Hypertensive Patients with Chronic Kidney Disease

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myelotha: A Matched Comparison to a Melphalan-Only Approach.

By Lahuerta Palacios, Juan José . Biology of Blood and Marrow Transplantation, 2013 . 19(1):69-74. , Formato Vancouver: Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013 Jan;19(1):69-74.

Place Hold on Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myelotha: A Matched Comparison to a Melphalan-Only Approach.

Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms.

By Arenas Cortés, Alicia | Ayala Díaz, Rosa María | Barrio García, Santiago | Gilsanz Rodríguez, Florinda | Jiménez Ubieto, Ana Isabel | Martínez López, Joaquín | Rapado Martínez, Inmaculada | Rueda Fernández, Daniel. Blood, 2013 . 161(5):667-76. , Formato Vancouver: Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D et al. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. Br J Haematol. 2013 Jun;161(5):667-76.

Place Hold on Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms.

Increased pulse pressure is associated with left atrial enlargement in resistant hypertensive patients.

By Ruilope Urioste, Luis Miguel. Blood Pressure, 2013 . 22(1):39-44. , Formato Vancouver: Armario P, Oliveras A, Hernández-Del-Rey R, Suárez C, Martell N, Ruilope LM et al. Investigators of Resistant Hypertension Registry of the Spanish Society of Hypertension. Increased pulse pressure is associated with left atrial enlargement in resistant hypertensive patients. Blood Press. 2013 Feb;22(1):39-44.

Place Hold on Increased pulse pressure is associated with left atrial enlargement in resistant hypertensive patients.

Handling Continuous Renal Replacement Therapy-Related Adverse Effects in Intensive Care Unit Patients: The Dialytrauma Concept.

By Sánchez-Izquierdo Riera, José Ángel. Blood Purification, 2012 . 34(2):177-85. , Formato Vancouver: Maynar Moliner J, Honore PM, Sánchez-Izquierdo Riera JA, Herrera Gutiérrez M, Spapen HD. Handling continuous renal replacement therapy-related adverse effects in intensive care unit patients: the dialytrauma concept. Blood Purif. 2012;34(2):177-85.

Place Hold on Handling Continuous Renal Replacement Therapy-Related Adverse Effects in Intensive Care Unit Patients: The Dialytrauma Concept.

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín | Martín Ramos, María Luisa. Blood, 2012 . 120(8):1589-96. , Formato Vancouver: Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J et al; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012 Aug 23;120(8):1589-96.

Place Hold on Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín. Blood, 2012 . 120(13):2581-8. , Formato Vancouver: Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, López de la Guía A, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012 Sep 27;120(13):2581-8.

Place Hold on Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín | Montalbán Pallarés, María Ángeles. Blood, 2012 . 119(3):687-91. , Formato Vancouver: Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-López J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012 Jan 19;119(3):687-91.

Place Hold on High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

MicroRNA signatures in B-cell lymphomas.

By Martínez González, Miguel Ángel. Blood Cancer Journal, 2012 . 2(2):e57. , Formato Vancouver: Di Lisio L, Sánchez-Beato M, Gómez-López G, Rodríguez ME, Montes-Moreno S, Mollejo M, et al. MicroRNA signatures in B-cell lymphomas. Blood Cancer J. 2012 Feb;2(2):e57.

Place Hold on MicroRNA signatures in B-cell lymphomas.

Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension

By Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Integrated Blood Pressure Control, 2011 . 4:27-34. , Formato Vancouver: Segura J, Ruilope LM. Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension. Integr Blood Press Control. 2011;4:27-34.

Place Hold on Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension

A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients

By García Donaire, José Antonio | Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Blood Pressure, 2011 . 20(6):322-334. , Formato Vancouver: García-Donaire JA, Segura J, Cerezo C, Ruilope LM. A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Press. 2011 Dec;20(6):322-34.

Place Hold on A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients

Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: The ESPADA study

By Campo, Carlos | Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Blood Pressure, 2000 . 9(6):355-362 , Formato Vancouver: Campo C, Fernández G, González Esteban J, Segura J, Ruilope LM. Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: the ESPADA study. Blood Press. 2000;9(6):355-62.

Place Hold on Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: The ESPADA study

miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy

By Grande García, Carlos. Blood, 2011 . 118(4):1034-1040. , Formato Vancouver: Montes Moreno S, Martínez N, Sánchez Espiridión B, Díaz Uriarte R, Rodriguez ME, Sáez A, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118(4):1034-40.

Place Hold on miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

By Grande García, Carlos | Lahuerta Palacios, Juan José | Martínez López, Joaquín. Blood, 2011 . 118(3):529-534. , Formato Vancouver: Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529-34.

Place Hold on Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

By Serna Torroba, Javier de la . Blood, 2011 . 117(6):1799-1805. , Formato Vancouver: Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011;117(6):1799-805.

Place Hold on Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage

By Serna Torroba, Javier de la . Blood Cells Molecules and Diseases, 2011 . 46(1):115-118. , Formato Vancouver: Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández Galán MA, Figueredo A, et al. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis. 2011 Jan 15;46(1):115-8.

Place Hold on Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

By Fernández Guijarro, Manuela | Lahuerta Palacios, Juan José | Martínez López, Joaquín | Martín Ramos, María Luisa | Montalbán Pallarés, María Ángeles. Blood, 2011 . 118(17):4547-4553 , Formato Vancouver: Mateos MV, Gutiérrez NC, Martín-Ramos ML, Paiva B, Montalbán MA, Oriol A, et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood. 2011 Oct 27;118(17):4547-53.

Place Hold on Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

By Ortiz Romero, Pablo Luis. Blood, 2011 . 118(15):4024-4035. , Formato Vancouver: Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011 Oct 13;118(15):4024-35.

Place Hold on EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma